{
  "title": "What this review means",
  "includeSubclaimIllustrations": false,
  "redteamReviewed": true,
  "accessNotice": "Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.",
  "overview": "Lifestyle treatment can improve MASH histology; fibrosis reversal, liver-death prevention and weight loss as the sole mediator require stronger direct evidence.",
  "implications": "The registered primary SC2 reaches Δ with Moderate confidence: a small randomized lifestyle package changes explicit steatohepatitis histology, while the older trial offers broader activity support. Direct original-body examination prevents calling fat-only NAS changes full resolution. Evidence does not yet map sufficiently broad baseline contexts or isolate achieved weight as the causal mediator to reach Ε or mechanistically narrowed convergence. Separate Γ fibrosis and surrogate-to-event companions do not erase the positive registered clinical phenotype.",
  "limitations": "Moderate confidence rests on a single small randomized trial of current MASH resolution that has not been replicated, a second randomized trial with mixed component results, and heterogeneous packages and comparators; it bounds the evidence base, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation."
}